The effect of tranexamic acid in reducing mortality and the need for blood transfusion in trauma patients with significant bleeding

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040816473N6

Enrollment

Registered

2016-05-29

Start date

2014-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Tranexamic acid. Condition 2: transfusion. Anticoagulant antagonists, vitamin K and other coagulants Blood transfusion (without reported diagnosis)

Interventions

Intervention 1: In case group: Tranexamic acid infusion. Intervention 2: In control group: placebo infusion.

Treatment - Drugs

In case group: Tranexamic acid infusion

In control group: placebo infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: age>5 years; Systolic blood pressure110; no indication for surgery

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mortallity. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Need for blood transfusion. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.	—

Secondary

Measure	Time frame
Hospitalization days in ICU. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Organ Failure. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Thrombotic complications. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.	—

Measure

Time frame

Hospitalization days in ICU. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Organ Failure. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Thrombotic complications. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Kakaei

Tabriz University of Medical Sciences

fkakaei@tbzmed.ac.ir+98 41 3334 1317

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026